Your browser is no longer supported. Please, upgrade your browser.
ALIM Alimera Sciences, Inc. daily Stock Chart
ALIM [NASD]
Alimera Sciences, Inc.
Index- P/E4.08 EPS (ttm)0.22 Insider Own1.16% Shs Outstand71.53M Perf Week-7.15%
Market Cap65.09M Forward P/E- EPS next Y-0.16 Insider Trans0.00% Shs Float69.26M Perf Month-9.00%
Income16.00M PEG- EPS next Q-0.05 Inst Own69.90% Short Float0.53% Perf Quarter-18.02%
Sales41.00M P/S1.59 EPS this Y47.70% Inst Trans1.38% Short Ratio4.21 Perf Half Y5.81%
Book/sh-0.39 P/B- EPS next Y- ROA28.80% Target Price2.63 Perf Year-30.00%
Cash/sh0.18 P/C5.17 EPS next 5Y- ROE-31.20% 52W Range0.74 - 1.38 Perf YTD-31.58%
Dividend- P/FCF- EPS past 5Y12.10% ROI87.00% 52W High-34.06% Beta1.29
Dividend %- Quick Ratio3.90 Sales past 5Y- Gross Margin89.30% 52W Low22.97% ATR0.06
Employees118 Current Ratio4.10 Sales Q/Q13.30% Oper. Margin-42.30% RSI (14)35.72 Volatility5.85% 4.93%
OptionableYes Debt/Eq- EPS Q/Q740.20% Profit Margin39.00% Rel Volume0.56 Prev Close0.94
ShortableYes LT Debt/Eq- EarningsNov 05 AMC Payout0.00% Avg Volume87.28K Price0.91
Recom2.00 SMA20-8.79% SMA50-8.89% SMA200-8.32% Volume49,480 Change-3.19%
Apr-27-17Initiated Rodman & Renshaw Buy $4
Nov-17-14Initiated Summer Street Research Buy $12
Sep-29-14Reiterated Northland Capital Outperform $7 → $10
Oct-28-13Upgrade Cowen Market Perform → Outperform
Oct-08-13Initiated Northland Capital Outperform $5
Nov-14-11Downgrade Rodman & Renshaw Mkt Outperform → Mkt Perform
Dec-27-10Reiterated Oppenheimer Outperform $16 → $14
Oct-11-10Initiated Rodman & Renshaw Mkt Outperform $13
Jun-02-10Initiated Oppenheimer Outperform $16
Dec-17-18 07:00AM  Alimera Sciences Announces Pricing Approval For ILUVIEN(R) in the U.A.E. ACCESSWIRE
Nov-29-18 07:15AM  Alimera Sciences Appoints Rick Eiswirth as Chief Executive Officer ACCESSWIRE
Nov-26-18 03:30PM  Alimera Sciences Announces Canadian Regulatory Approval for ILUVIEN(R) ACCESSWIRE
Nov-21-18 08:25AM  Consolidated Research: 2018 Summary Expectations for Texas Instruments, Sino-Global Shipping America, Alimera Sciences, Sypris Solutions, JetPay, and Performant Financial Fundamental Analysis, Key Performance Indications GlobeNewswire
Nov-18-18 09:30PM  Edited Transcript of ALIM earnings conference call or presentation 6-Nov-18 2:00pm GMT Thomson Reuters StreetEvents
Nov-09-18 06:30AM  Alimera Sciences to Present at Upcoming Investor Conferences ACCESSWIRE
Nov-06-18 07:30AM  Alimera Sciences (ALIM) Reports Q3 Loss, Tops Revenue Estimates Zacks
05:03AM  Alimera Sciences: 3Q Earnings Snapshot Associated Press
Nov-05-18 06:45PM  Alimera Sciences Reports Third Quarter 2018 Results ACCESSWIRE
Oct-23-18 04:45PM  Alimera Sciences to Report Third Quarter 2018 Results November 5, 2018 ACCESSWIRE
Oct-22-18 04:30PM  Alimera Sciences Announces Six ILUVIEN(R) Posters to be Presented at 2018 American Academy of Ophthalmology ACCESSWIRE
Oct-15-18 03:57PM  How Alimera Sciences Inc (NASDAQ:ALIM) Can Impact Your Portfolio Volatility Simply Wall St.
Sep-17-18 05:32PM  Alimera Sciences Announces Nine Clinical Presentations and a Sponsored Symposium at 18th EURETINA Congress PR Newswire
Sep-13-18 04:30PM  Alimera Sciences Announces Three Podium Presentations for ILUVIEN® to be Presented at 2018 Retina Society's Annual Meeting PR Newswire
Sep-04-18 05:43PM  Alimera Sciences Announces Exchange of Series B Preferred Stock for Newly Issued Series C Preferred Stock PR Newswire
Aug-29-18 07:30AM  Alimera Sciences to Present at the 20th Annual HC Wainwright Global Investment Conference PR Newswire
Aug-28-18 07:30AM  Alimera Sciences to Present at the Annual B. Riley Healthcare Conference PR Newswire
Aug-23-18 06:42AM  Alimera Sciences Sees Hammer Chart Pattern: Time to Buy? Zacks
Aug-06-18 09:19PM  Edited Transcript of ALIM earnings conference call or presentation 31-Jul-18 1:00pm GMT Thomson Reuters StreetEvents -11.99%
Jul-31-18 07:00AM  Alimera Sciences, Inc. to Host Earnings Call ACCESSWIRE
Jul-30-18 05:41PM  Alimera Sciences: 2Q Earnings Snapshot Associated Press
04:30PM  Alimera Sciences Reports Second Quarter 2018 Results PR Newswire
Jul-18-18 07:30AM  Alimera Sciences to Report Second Quarter 2018 Results July 30, 2018 PR Newswire +10.10%
Jul-11-18 07:30AM  Alimera Sciences Announces 8 ILUVIEN® Presentations At The 2018 American Society Of Retina Specialists Annual Meeting PR Newswire
Jul-05-18 09:10AM  Alimera Stock Grew 25 Percent and It Is Just Getting Warmed Up InvestorPlace
Jun-29-18 02:50PM  B. Riley FBR: 3 Reasons To Buy Alimera Sciences Benzinga +6.35%
Jun-27-18 11:24AM  When Will Alimera Sciences Inc (NASDAQ:ALIM) Turn A Profit? Simply Wall St.
Jun-21-18 07:30AM  Alimera Sciences Appoints Mary T. Szela to its Board of Directors PR Newswire
Jun-11-18 07:30AM  The UK National Institute For Health And Care Excellence To Undertake A Partial Review Of The ILUVIEN Reimbursement Guidance Allowing Broader Availability PR Newswire
Jun-04-18 07:30AM  Alimera Sciences Terminates At-the-Market Offering Agreement PR Newswire
May-31-18 07:30AM  Alimera Sciences Announces the Reimbursement of ILUVIEN® in Spain PR Newswire
May-22-18 07:30AM  Alimera Sciences to Present at the 8th Annual LD Micro Invitational Conference PR Newswire
May-08-18 10:11AM  Edited Transcript of ALIM earnings conference call or presentation 3-May-18 1:00pm GMT Thomson Reuters StreetEvents -5.41%
May-02-18 04:15PM  Alimera Sciences Reports First Quarter 2018 Results ACCESSWIRE
Apr-24-18 04:30PM  Alimera Sciences to Report First Quarter 2018 Results May 2, 2018 ACCESSWIRE
07:30AM  Alimera Sciences Announces Data from 19 Iluvien(R) Studies to be Presented at 2018 ARVO ACCESSWIRE
Mar-02-18 06:05AM  Edited Transcript of ALIM earnings conference call or presentation 1-Mar-18 2:00pm GMT Thomson Reuters StreetEvents
Mar-01-18 07:40AM  Alimera Sciences, Inc. to Host Earnings Call ACCESSWIRE
Feb-28-18 07:19PM  Alimera Sciences reports 4Q loss Associated Press
04:30PM  Alimera Sciences Reports Fourth Quarter and Full Year 2017 Financial Results GlobeNewswire
Feb-27-18 07:30AM  Alimera Sciences to Present at the 38th Annual Cowen & Co. Health Care Conference GlobeNewswire
Feb-14-18 07:30AM  Alimera Sciences to Report Fourth Quarter and Full Year 2017 Results on February 28, 2018 GlobeNewswire +9.09%
Jan-08-18 07:30AM  Alimera Sciences Refinances Debt With New $40 Million Debt Facility From Solar Capital GlobeNewswire
Jan-04-18 07:30AM  Alimera Sciences Receives Acceptance of Filing to Obtain Approval for ILUVIEN® Non-Infectious Posterior Uveitis Indication in Europe GlobeNewswire
Dec-18-17 02:26PM  ETFs with exposure to Alimera Sciences, Inc. : December 18, 2017 Capital Cube
Dec-11-17 07:30AM  Alimera Sciences Announces Patients Now Being Treated With ILUVIEN® In Ireland GlobeNewswire
Dec-08-17 12:19PM  ETFs with exposure to Alimera Sciences, Inc. : December 8, 2017 Capital Cube
Nov-28-17 11:00AM  Alimera Sciences to Present at the 10th Annual LD Micro Conference Marketwired
Nov-21-17 11:15AM  ETFs with exposure to Alimera Sciences, Inc. : November 21, 2017 Capital Cube
Nov-09-17 11:45AM  ETFs with exposure to Alimera Sciences, Inc. : November 9, 2017 Capital Cube
Nov-08-17 02:53PM  Alimera Sciences, Inc. :ALIM-US: Earnings Analysis: Q3, 2017 By the Numbers : November 8, 2017 Capital Cube
07:30AM  Alimera Sciences Announces Nine iluvien® data sets to be Presented at 2017 american academy of ophthalmology GlobeNewswire
Nov-07-17 07:30AM  Alimera Sciences' CEO Dan Myers to Present During Ophthalmology Innovation Summit at American Academy of Ophthalmology 2017 GlobeNewswire
Nov-06-17 06:36PM  Edited Transcript of ALIM earnings conference call or presentation 2-Nov-17 1:00pm GMT Thomson Reuters StreetEvents
Nov-02-17 07:20AM  ALIMERA SCIENCES INC to Host Earnings Call ACCESSWIRE +5.65%
05:46AM  Alimera Sciences reports 3Q loss Associated Press
Nov-01-17 05:37PM  Alimera Sciences Reports Third Quarter 2017 Financial Results GlobeNewswire
Oct-25-17 01:30PM  Alimera Sciences to Report Third Quarter 2017 Results November 1st, 2017 GlobeNewswire
09:47AM  ETFs with exposure to Alimera Sciences, Inc. : October 25, 2017 Capital Cube
Oct-10-17 10:58AM  ETFs with exposure to Alimera Sciences, Inc. : October 10, 2017 Capital Cube
Oct-03-17 07:30AM  Alimera Sciences Announces Four Data Sets for ILUVIEN® to Be Presented at 2017 Retina Societys Annual Meeting GlobeNewswire
Sep-29-17 10:21AM  ETFs with exposure to Alimera Sciences, Inc. : September 29, 2017 Capital Cube
Sep-19-17 09:25AM  Alimera Sciences to Present at the Sidoti & Company Fall 2017 Conference GlobeNewswire
Sep-12-17 04:01PM  Alimera Sciences Announces ILUVIEN® now available in Ireland GlobeNewswire
Sep-11-17 04:01PM  Weather Related Conditions Cancels Alimera Sciences Presentation at Rodman & Renshaw Global Investment Conference GlobeNewswire
Sep-08-17 11:16PM  ETFs with exposure to Alimera Sciences, Inc. : September 9, 2017 Capital Cube
Sep-07-17 08:39AM  Alimera Sciences, Inc. :ALIM-US: Earnings Analysis: Q2, 2017 By the Numbers : September 7, 2017 Capital Cube
Sep-05-17 07:30AM  Alimera Sciences Announces 9 Clinical Presentations and a Sponsored Symposium at 17th Euretina Congress GlobeNewswire
Aug-31-17 04:01PM  Alimera Sciences to Present at the 19th Annual Rodman & Renshaw Global Investment Conference GlobeNewswire
Aug-29-17 04:05PM  Alimera Sciences Signs Agreement for Exclusive Distributor of ILUVIEN® in France GlobeNewswire
Aug-13-17 02:46AM  Edited Transcript of ALIM earnings conference call or presentation 3-Aug-17 1:00pm GMT Thomson Reuters StreetEvents
Aug-09-17 07:30AM  Alimera Sciences Announces Data to be Presented at the 2017 Annual ASRS Meeting GlobeNewswire
Aug-07-17 07:30AM  Alimera Sciences' CEO Dan Myers to Present U.S. Real-World ILUVIEN® Post-Marketing Data During Ophthalmology Innovation Summit at ASRS, August 10, 2017 GlobeNewswire
Aug-04-17 01:08AM  Alimera Sciences reports 2Q loss Associated Press
Aug-03-17 07:05AM  Investor Network: ALIMERA SCIENCES INC to Host Earnings Call ACCESSWIRE +5.63%
Jul-25-17 04:05PM  Alimera Sciences Announces Real-World Audit Data Supporting the Positive Benefits of ILUVIEN® Treatment GlobeNewswire
Jul-24-17 11:00AM  Alimera Sciences to Report Second Quarter 2017 Financial Results on August 2nd, 2017 GlobeNewswire
Jul-19-17 04:05PM  Positive Results Enable Alimera Sciences to Reduce Enrollment in ILUVIEN® Registry Safety Study in the U.K. GlobeNewswire
Jul-13-17 03:26PM  ETFs with exposure to Alimera Sciences, Inc. : July 13, 2017 Capital Cube
Jul-12-17 09:45AM  Alimera Sciences Announces Italian Patients Now Being Treated With ILUVIEN® GlobeNewswire +5.63%
09:30AM  The Zacks Analyst Blog Highlights: Vertex Pharmaceuticals, Alimera Sciences, Enzo Biochem, Sarepta Therapeutics and EXACT Sciences Zacks
Jul-11-17 09:26AM  5 Top Multibagger Biotech Stocks to Buy in the 2nd Half Zacks
Jul-10-17 04:56PM  Alimera Sciences To Expand ILUVIEN® Indication in Europe for Posterior Uveitis GlobeNewswire
04:01PM  pSivida Out-licenses EMEA Rights for Durasert Three-year Treatment for Posterior Segment Uveitis While Retaining U.S. Commercial Rights; Amended Global Collaboration Agreement with Alimera for ILUVIEN® Improves pSividas Revenue Generation GlobeNewswire
Jun-29-17 02:50PM  ETFs with exposure to Alimera Sciences, Inc. : June 29, 2017 Capital Cube
Jun-16-17 03:20PM  ETFs with exposure to Alimera Sciences, Inc. : June 16, 2017 Capital Cube
Jun-14-17 09:39AM  Alimera Sciences, Inc. :ALIM-US: Earnings Analysis: Q1, 2017 By the Numbers : June 14, 2017 Capital Cube
Jun-02-17 08:15AM  Blog Coverage Eli Lilly's Late-Stage Bladder Cancer Drug CYRAMZA Meets Primary Endpoint Accesswire
May-18-17 11:16AM  Edited Transcript of ALIM earnings conference call or presentation 9-May-17 12:00pm GMT Thomson Reuters StreetEvents
May-12-17 11:55AM  Edited Transcript of ALIM earnings conference call or presentation 9-May-17 12:00pm GMT Thomson Reuters StreetEvents
May-09-17 07:00AM  Investor Network: ALIMERA SCIENCES INC to Host Earnings Call Accesswire +5.52%
May-08-17 06:11PM  Alimera Sciences reports 1Q loss Associated Press -5.23%
04:58PM  Alimera Sciences Reports First Quarter 2017 Financial Results GlobeNewswire
May-03-17 02:42PM  Alimera Sciences to Report First Quarter 2017 Financial Results on May 8th, 2017 GlobeNewswire
May-01-17 03:34PM  ETFs with exposure to Alimera Sciences, Inc. : May 1, 2017 Capital Cube
07:30AM  Alimera Sciences Announces Data From 27 ILUVIEN® Studies to Be Presented at 2017 ARVO GlobeNewswire
Apr-20-17 02:11PM  ETFs with exposure to Alimera Sciences, Inc. : April 20, 2017 Capital Cube
Apr-07-17 03:44PM  ETFs with exposure to Alimera Sciences, Inc. : April 7, 2017 Capital Cube
Mar-27-17 03:48PM  ETFs with exposure to Alimera Sciences, Inc. : March 27, 2017 Capital Cube
03:48PM  ETFs with exposure to Alimera Sciences, Inc. : March 27, 2017
Alimera Sciences, Inc., a pharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals in the United States and internationally. It focuses on diseases affecting the back of the eye or retina. The company offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness. Its ILUVIEN is inserted in the back of the patient's eye in a non-surgical procedure, which allows for a self-sealing wound by delivering a continuous microdose of the non-proprietary corticosteroid fluocinolone acetonide in the eye. The company has an agreement with pSivida US, Inc. for the development and sale of ILUVIEN, and a proprietary insert technology to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans or to treat DME. It sells its products through sales force, as well as through distributors. The company serves physician offices, pharmacies, and hospitals. Alimera Sciences, Inc. was founded in 2003 and is headquartered in Alpharetta, Georgia.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
EISWIRTH RICHARD S JRPresident and CFOMay 07Buy1.0510,00010,500171,770May 07 04:29 PM
ARMISTICE CAPITAL, LLC10% OwnerFeb 06Buy1.128,0008,9606,936,000Feb 09 06:31 PM
ARMISTICE CAPITAL, LLC10% OwnerFeb 05Buy1.144,0004,5606,928,000Feb 09 06:31 PM
ARMISTICE CAPITAL, LLC10% OwnerFeb 02Buy1.168,0009,2806,924,000Feb 09 06:31 PM
EISWIRTH RICHARD S JRPresident and CFOJan 19Sale1.186,8098,03677,970Jan 19 04:39 PM
Green KennethSVP & Chief Scientific OfficerJan 19Sale1.185,4046,378170,634Jan 19 04:39 PM
Holland DavidSVP of Sales and MarketingJan 19Sale1.1812,75015,048109,588Jan 19 04:40 PM
Myers C. DanielCEOJan 19Sale1.1826,45031,21675,061Jan 19 04:40 PM
Ashman PhilipSVP, EU Managing DirectorJan 19Sale1.1812,75015,0480Jan 19 04:39 PM
EISWIRTH RICHARD S JRPresident and CFOJan 18Sale1.226,6018,02784,779Jan 19 04:39 PM
Green KennethSVP & Chief Scientific OfficerJan 18Sale1.225,2346,365176,038Jan 19 04:39 PM
Holland DavidSVP of Sales and MarketingJan 18Sale1.2212,75015,504122,338Jan 19 04:40 PM
Myers C. DanielCEOJan 18Sale1.2226,45032,163101,511Jan 19 04:40 PM
Ashman PhilipSVP, EU Managing DirectorJan 18Sale1.2212,75015,50412,750Jan 19 04:39 PM
Myers C. DanielCEOJan 17Sale1.2326,45032,560127,961Jan 18 04:53 PM
Ashman PhilipSVP, EU Managing DirectorJan 17Sale1.2312,75015,69525,500Jan 18 04:53 PM
Green KennethSVP & Chief Scientific OfficerJan 17Sale1.235,7397,065181,272Jan 18 04:54 PM
Holland DavidSVP of Sales and MarketingJan 17Sale1.2312,75015,695135,088Jan 18 04:54 PM
EISWIRTH RICHARD S JRPresident and CFOJan 17Sale1.237,2398,91191,380Jan 18 04:53 PM
Myers C. DanielCEOJan 16Sale1.2426,45032,735154,411Jan 18 04:53 PM
Ashman PhilipSVP, EU Managing DirectorJan 16Sale1.2412,75015,77938,250Jan 18 04:53 PM
Green KennethSVP & Chief Scientific OfficerJan 16Sale1.245,7507,116187,011Jan 18 04:54 PM
Holland DavidSVP of Sales and MarketingJan 16Sale1.2412,75015,779147,838Jan 18 04:54 PM
EISWIRTH RICHARD S JRPresident and CFOJan 16Sale1.247,2558,97998,619Jan 18 04:53 PM